Project Grant R21HL185889
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $426K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Kansas City, KS 66160, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Beth Israel Deaconess Medical Center, Inc. $852,908 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to design and optimize elastin-like polypeptide (ELP) nanoparticles for pulmonary gene therapy of cystic fibrosis. The funded work develops fourth-generation ELP nanoparticles engineered to self-assemble into pH-responsive micellar nanoparticles for cytosolic delivery of mRNA, pDNA, proteins, and RNPs to...
- The National Heart, Lung and Blood Institute awarded Cincinnati Children's Hospital Medical Center $3.193 million on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to non-invasively quantify alveolar remodeling in cystic fibrosis lung disease using hyperpolarized xenon MRI. The research aims to establish the prevalence and short-term trajectories of emphysema-like remodeling in people with cystic fibrosis receiving CFTR modulator therapy. Cincinnati Children's...
- The National Heart, Lung, and Blood Institute awarded The University of Iowa $599,466 on August 19, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research examining the cellular and molecular mechanisms driving submucosal gland hypertrophy in chronic lung diseases including asthma, COPD, and cystic fibrosis. The funded research will identify fundamental pathways responsible for pathological gland enlargement by defining key cell-cell interactions and signaling...
- The National Heart, Lung, and Blood Institute awarded $742,459 to Rutgers The State University of New Jersey, doing business as RBHS-School of Nursing, on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The recipient is conducting a comprehensive epidemiologic study evaluating treatment optimization among people with cystic fibrosis in the era of highly effective modulator therapy. The study leverages the Cystic Fibrosis Foundation Patient Registry linked to...
- The National Heart, Lung, and Blood Institute awarded Boston Children's Hospital $1,561,052 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate pulmonary ionocyte function and development using human induced pluripotent stem cell-derived airway epithelium. Performance runs through June 30, 2030, in Boston, Massachusetts. The project addresses gaps in understanding how pulmonary ionocytes—rare airway cells marked by FOXI1 and ASCL3 expression and...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $441,375 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 15, 2025, with completion targeted for July 31, 2027. The award funds research to develop and optimize a dual adeno-associated virus (AAV) gene delivery system employing intein technology to deliver full-length, functional cystic fibrosis transmembrane...
- The National Heart, Lung, and Blood Institute awarded the University of Kansas Medical Center Research Institute, Inc. $1.405578 million on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to validate inflammatory and hypoinflammatory endotypes in idiopathic pulmonary fibrosis and establish a molecular classification system to inform precision medicine treatment approaches. The recipient will conduct an in-depth proteomic analysis of bronchoalveolar lavage...
- The National Heart Lung and Blood Institute awarded the University of North Carolina at Chapel Hill $777,419 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the muco-obstructive mechanisms underlying bronchiectasis and identify novel therapeutic targets. The research examines bronchiectasis pathogenesis through a revised conceptual model that integrates airway epithelial hypoxia, mucus hyperconcentration, osmotic pressure-driven airway...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded National Jewish Health $249,000 on July 24, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate rare airway cell function in post-viral chronic inflammation. The research examines the role of microfold (M) cells in the post-influenza lung, particularly their contribution to secondary bacterial infection susceptibility and host protection. Using single-nucleus transcriptomic and...
- The National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $678,379 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to study the cellular biology and function of pulmonary ionocytes. The research investigates pulmonary ionocytes, rare epithelial cells in surface airway epithelium and submucosal glands that highly express the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ionocytes regulate airway surface...